Related Experiment Videos
Intracerebral choriocarcinoma.
W B Jones1, K M Wagner-Reiss, J L Lewis
1Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Gynecologic Oncology
|August 1, 1990
Summary
Gestational trophoblastic disease (GTD) brain metastases occurred in 9% of patients. Methotrexate, actinomycin D, and chlorambucil (MAC) chemotherapy showed limited success in preventing or treating brain metastases, with a 26.3% survival rate.
Area of Science:
- Oncology
- Neurology
- Gynecology
Background:
- Gestational trophoblastic disease (GTD) can metastasize to the brain.
- Brain metastases represent a significant challenge in GTD management.
Purpose of the Study:
- To review outcomes of patients with GTD metastatic to the brain.
- To evaluate the role of methotrexate, actinomycin D, and chlorambucil (MAC) chemotherapy in these patients.
Main Methods:
- Retrospective review of 19 patients with GTD metastatic to the brain treated between 1967 and 1987.
- Analysis of chemotherapy regimens, including MAC, and whole-brain radiotherapy.
Main Results:
- Brain metastases occurred in 9.0% of GTD patients.
- 26.3% (5/19) of patients with brain metastases survived long-term.
- MAC chemotherapy did not consistently prevent brain metastases and was less effective in resistant cases.
Conclusions:
- Whole-brain radiotherapy was standard treatment.
- The efficacy of MAC chemotherapy in preventing or treating GTD brain metastases appears limited.
- Further research into optimal treatment strategies for GTD brain metastases is warranted.